{"id":3132,"date":"2025-10-08T16:25:51","date_gmt":"2025-10-08T14:25:51","guid":{"rendered":"https:\/\/genocan.eu\/?p=3132"},"modified":"2025-10-17T16:56:18","modified_gmt":"2025-10-17T14:56:18","slug":"genetics-of-the-rhodesian-ridgeback-population-findings-from-400-tested-dogs","status":"publish","type":"post","link":"https:\/\/genocan.eu\/cs\/nezarazene\/genetics-of-the-rhodesian-ridgeback-population-findings-from-400-tested-dogs\/","title":{"rendered":"Genetika rhod\u00e9sk\u00e9ho ridgebacka: V\u00fdsledky 400 geneticky vy\u0161et\u0159en\u00fdch ps\u016f"},"content":{"rendered":"<p>V\u00e1\u017een\u00ed chovatel\u00e9, r\u00e1di bychom se s v\u00e1mi pod\u011blili o data z genetick\u00e9ho testov\u00e1n\u00ed. V\u011b\u0159\u00edme, \u017ee v\u00e1m pomohou se l\u00e9pe zorientovat v genetice rhod\u00e9sk\u00fdch ridgeback\u016f. <\/p>\n\n\n\n<p>N\u00ed\u017ee je uvedena souhrnn\u00e1 tabulka zahrnuj\u00edc\u00ed v\u0161echny genetick\u00e9 choroby a znaky hodnocen\u00e9 v testov\u00e1n\u00ed bal\u00ed\u010dku RR PANEL + RRIVA (<a href=\"https:\/\/genocan.eu\/cs\/breed\/rhodesky-ridgeback\/\">Rhod\u00e9sk\u00fd ridgeback &#8211; GenoCan.eu<\/a>). \u00dadaje odr\u00e1\u017eej\u00ed v\u00fdsledky od 400 ps\u016f plemene rhod\u00e9sk\u00fd ridgeback z cel\u00e9 Evropy, p\u0159i\u010dem\u017e v\u011bt\u0161ina vzork\u016f poch\u00e1z\u00ed z \u010cesk\u00e9 republiky, Slovenska, N\u011bmecka, Nizozemska, D\u00e1nska, Francie, \u0160v\u00e9dska, Norska, Rakouska a Spojen\u00e9ho kr\u00e1lovstv\u00ed. Pod tabulkou naleznete podrobn\u011bj\u0161\u00ed a komentovan\u00e9 v\u00fdsledky jednotliv\u00fdch onemocn\u011bn\u00ed\/znak\u016f.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Znak \/ onemocn\u011bn\u00ed<\/th><th>Referen\u010dn\u00ed (bez varianty)<\/th><th>P\u0159ena\u0161e\u010d<\/th><th>V riziku<\/th><\/tr><\/thead><tbody><tr><td><strong>Predispozice pro ridge (RIDGE)<\/strong><\/td><td><strong>R\/R:<\/strong> 50 % (200)<\/td><td><strong>R\/r:<\/strong> 50 % (200)<\/td><td><strong>r\/r:<\/strong> 0 % (0)<\/td><\/tr><tr><td><strong>Juveniln\u00ed myoklonick\u00e1 epilepsie (JME)<\/strong><\/td><td><strong>N\/N:<\/strong> 94 % (376)<\/td><td><strong>P\/N:<\/strong> 6 % (24)<\/td><td><strong>P\/P:<\/strong> 0 % (0)<\/td><\/tr><tr><td><strong>Malign\u00ed hypertermie (MH)<\/strong><\/td><td><strong>N\/N:<\/strong> 100 % (400)<\/td><td><strong>P\/N:<\/strong> 0 % (0)<\/td><td><strong>P\/P:<\/strong> 0 % (0)<\/td><\/tr><tr><td><strong>Degenerativn\u00ed myelopatie (DM)<\/strong><\/td><td><strong>N\/N:<\/strong> 91 % (364)<\/td><td><strong>P\/N:<\/strong> 9 % (36)<\/td><td><strong>P\/P:<\/strong> 0 % (0)<\/td><\/tr><tr><td><strong>Lokus D (\u0159ed\u011bn\u00ed barvy) \u2013 DLOK<\/strong><\/td><td><strong>D\/D:<\/strong> 93 % (372)<\/td><td><strong>D\/d1:<\/strong> 7 % (28)<\/td><td><strong>d1\/d1:<\/strong> 0 % (0)<\/td><\/tr><tr><td><strong>Lokus B (hn\u011bd\u00e1) \u2013 BLOK<\/strong><\/td><td><strong>B\/B:<\/strong> 71 % (284)<\/td><td><strong>B\/b:<\/strong> 25 % (100)<\/td><td><strong>b\/b:<\/strong> 4 % (16)<\/td><\/tr><tr><td><strong>Hemofilie B (HEMB)<\/strong><\/td><td><strong>N\/N:<\/strong> 100 % (400)<\/td><td><strong>P\/N:<\/strong> 0 % (0)<\/td><td><strong>P\/P:<\/strong> 0 % (0)<\/td><\/tr><tr><td><strong>\u010casn\u00e1 ztr\u00e1ta sluchu (EOAD)<\/strong><\/td><td><strong>N\/N:<\/strong> 96 % (384)<\/td><td><strong>P\/N:<\/strong> 4 % (16)<\/td><td><strong>P\/P:<\/strong> 0 % (0)<\/td><\/tr><tr><td><strong>D\u011bdi\u010dn\u00e1 komorov\u00e1 arytmie (RR IVA)<\/strong><\/td><td><strong>N\/N: <\/strong>60% (239)<\/td><td><strong>P\/N: <\/strong>38% (151)<\/td><td><strong>P\/P: <\/strong>2.5% (10)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><em>Pozn.: N = referen\u010dn\u00ed (\u201ewild-type\u201c) alela; P = patogenn\u00ed varianta. Procenta jsou z n = 400 a po\u010dty jsou zaokrouhlen\u00e9 na cel\u00e9 psy. RIDGE: alela <strong>R<\/strong> nese predispozici pro ridge (R\/R nebo R\/r); <strong>r\/r<\/strong> je ridgeless.<\/em> <em>DLOK\/BLOK jsou lokusy barvy srsti (nejde o onemocn\u011bn\u00ed): <strong>d1<\/strong> = varianta \u0159ed\u011bn\u00ed; <strong>b<\/strong> = varianta hn\u011bd\u00e9.<\/em><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Predispozice pro ridge (RIDGE)<\/h2>\n\n\n\n<p>Na z\u00e1klad\u011b testov\u00e1n\u00ed 400 rhod\u00e9sk\u00fdch ridgeback\u016f pro predispozici pro ridge m\u016f\u017eeme konstatovat, \u017ee pod\u00edl ridgeback\u016f je p\u0159esn\u011b 1:1<strong> R\/R (Ridge\/Ridge) a R\/r (Ridge\/ridgeless)<\/strong>. R\/R psi typicky neprodukuj\u00ed ridgeless potomky; naproti tomu p\u00e1\u0159en\u00ed <strong>R\/r \u00d7 R\/r<\/strong> nese riziko vy\u0161\u0161\u00edho pod\u00edlu ridgeless \u0161t\u011b\u0148at.<br>Z laboratorn\u00edch dat d\u00e1le vypl\u00fdv\u00e1, \u017ee <strong> R\/R <strong>psi<\/strong> maj\u00ed zhruba 2\u00d7 vy\u0161\u0161\u00ed riziko dermoidn\u00edho sinu (DS) nebo nepravidelnost\u00ed ridge (multikorunky)<\/strong> ve srovn\u00e1n\u00ed s R\/r. I proto jsou pravd\u011bpodobn\u011b <strong>R\/r jedinci preferovan\u00fdm genotypem<\/strong> mezi chovateli, co\u017e m\u016f\u017ee vysv\u011btlovat jejich relativn\u011b vysokou frekvenci v populaci, p\u0159esto\u017ee nesou riziko ridgeless \u0161t\u011b\u0148at p\u0159i p\u00e1\u0159en\u00ed s dal\u0161\u00edm R\/r.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Juveniln\u00ed myoklonick\u00e1 epilepsie (JME)<\/h2>\n\n\n\n<p>JME je d\u011bdi\u010dn\u00e1 epilepsie rhod\u00e9sk\u00fdch ridgeback\u016f charakterizovan\u00e1 myoklonick\u00fdmi (z\u00e1\u0161kubov\u00fdmi) z\u00e1chvaty s po\u010d\u00e1tkem v ml\u00e1d\u00ed. V na\u0161em souboru 400 ps\u016f bylo <strong>~6 % p\u0159ena\u0161e\u010d\u016f<\/strong> JME varianty.<br><strong>D\u011bdi\u010dnost &amp; riziko (autozom\u00e1ln\u011b recesivn\u00ed):<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>P\u0159ena\u0161e\u010d \u00d7 P\u0159ena\u0161e\u010d (P\/N \u00d7 P\/N):<\/strong> 25 % posti\u017een\u00ed (P\/P), 50 % p\u0159ena\u0161e\u010di (P\/N), 25 % norm\u00e1ln\u00ed (N\/N).<\/li>\n\n\n\n<li><strong>P\u0159ena\u0161e\u010d \u00d7 Norm\u00e1ln\u00ed (P\/N \u00d7 N\/N):<\/strong> 0 % posti\u017een\u00ed; 50 % p\u0159ena\u0161e\u010di, 50 % norm\u00e1ln\u00ed.<\/li>\n\n\n\n<li><strong>Norm\u00e1ln\u00ed \u00d7 Norm\u00e1ln\u00ed (N\/N \u00d7 N\/N):<\/strong> 100 % norm\u00e1ln\u00ed<\/li>\n<\/ul>\n\n\n\n<p><strong>Chovatelsk\u00e9 doporu\u010den\u00ed:<\/strong> Vyhn\u011bte se p\u00e1\u0159en\u00ed <strong>P\/N \u00d7 P\/N<\/strong>, abyste eliminovali 25% riziko posti\u017een\u00fdch \u0161t\u011b\u0148at. P\u00e1rov\u00e1n\u00ed p\u0159ena\u0161e\u010d\u016f s geneticky norm\u00e1ln\u00edmi psi (N\/N) br\u00e1n\u00ed narozen\u00ed posti\u017een\u00fdch \u0161t\u011b\u0148at, ale z\u00e1rove\u0148 zachov\u00e1v\u00e1 genetickou diverzitu. <\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Malign\u00ed hypertermie (MH)<\/h2>\n\n\n\n<p>MH je <strong>autozom\u00e1ln\u011b dominantn\u00ed<\/strong> onemocn\u011bn\u00ed: psi nesouc\u00ed patogenn\u00ed variantu (P\/N) jsou v riziku malign\u00ed hypertermie \u2014 anest\u00e9zi\u00ed navozen\u00e9 krize s rychl\u00fdm p\u0159eh\u0159\u00e1t\u00edm a t\u011b\u017ekou svalovou ztuhlost\u00ed. V na\u0161em souboru 400 RR <strong>nebyl detekov\u00e1n \u017e\u00e1dn\u00fd pozitivn\u00ed jedinec<\/strong> (100 % N\/N), co\u017e nazna\u010duje velmi n\u00edzk\u00fd nebo nulov\u00fd v\u00fdskyt malign\u00ed hypertermie v populaci RR.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Degenerativn\u00ed myelopatie (DM)<\/h2>\n\n\n\n<p>DM je pozdn\u011b nastupuj\u00edc\u00ed, progresivn\u00ed nervosvalov\u00e9 onemocn\u011bn\u00ed. Po\u010d\u00e1te\u010dn\u00ed p\u0159\u00edznaky mohou zahrnovat poruchu rovnov\u00e1hy, povolen\u00fd ocas, tah\u00e1n\u00ed p\u00e1nevn\u00edch kon\u010detin, inkontinenci a postupn\u011b a\u017e ochrnut\u00ed p\u00e1nevn\u00edch kon\u010detin.<\/p>\n\n\n\n<p><strong>V\u00fdsledky v kohort\u011b (n = 400):<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Norm\u00e1ln\u00ed (N\/N): ~91 % &#8211; 364\/400<\/li>\n\n\n\n<li>P\u0159ena\u0161e\u010di (P\/N): ~9 % &#8211; 36\/400<\/li>\n\n\n\n<li>V riziku (P\/P): 0 % &#8211; nedetekov\u00e1no<\/li>\n<\/ul>\n\n\n\n<p><strong>Genetika &amp; penetrance DM:<\/strong> DM u ps\u016f je nej\u010dast\u011bji spojena s variantou v <strong>SOD1<\/strong> a vykazuje <strong>ne\u00faplnou penetranci<\/strong> \u2014 ne v\u0161ichni P\/P jedinci onemocn\u00ed; jin\u00e9 nervosvalov\u00e9 poruchy mohou p\u0159\u00edznaky napodobovat. Genetick\u00fd status informuje o riziku, klinick\u00e9 vy\u0161et\u0159en\u00ed je v\u0161ak st\u00e1le z\u00e1sadn\u00ed.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Lokus D (\u0159ed\u011bn\u00ed) \u2014 DLOK<\/h2>\n\n\n\n<p>D-lokus \u0159\u00edd\u00ed <strong>\u0159ed\u011bn\u00ed pigmentu<\/strong>. Testovan\u00e1 varianta <strong>d1<\/strong> sni\u017euje intenzitu pigmentu. U rhod\u00e9sk\u00fdch ridgeback\u016f vede \u0159ed\u011bn\u00ed k zesv\u011btlen\u00ed typick\u00e9ho \u201ered-wheaten\u201c zbarven\u00ed do kr\u00e9mov\u00fdch\/st\u0159\u00edbrn\u00fdch odst\u00edn\u016f.<\/p>\n\n\n\n<p><strong>Na\u0161e kohorta (n = 400):<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>norm\u00e1ln\u00ed &#8211; D\/D: 93 % (372)<\/li>\n\n\n\n<li>p\u0159ena\u0161e\u010di &#8211; D\/d1: 7 % (28)<\/li>\n\n\n\n<li>\u0159ed\u011bn\u00ed d1\/d1: 0 % (0)<\/li>\n<\/ul>\n\n\n\n<p><strong>Pozn.:<\/strong> \u0158ed\u011bn\u00ed prim\u00e1rn\u011b ovliv\u0148uje pigment, <strong>nejde o onemocn\u011bn\u00ed<\/strong>. U n\u011bkter\u00fdch plemen se s \u0159ed\u011bn\u00ed m\u016f\u0159e pojit s ko\u017en\u00edmi pot\u00ed\u017eemi (nap\u0159. alopecie z \u0159ed\u011bn\u00ed barvy), prevalence se v\u0161ak mezi plemeny li\u0161\u00ed.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Lokus B (hn\u011bd\u00e1) \u2014 BLOK<\/h2>\n\n\n\n<p>B-lokus ur\u010duje pom\u011br hn\u011bd\u00e9ho vs. \u010dern\u00e9ho eumelaninu. Testuj\u00ed se <strong>t\u0159i varianty<\/strong> (ka\u017ed\u00e1 predisponuje k hn\u011bd\u00e9mu zbarven\u00ed) a d\u011bdi\u010dnost je <strong>autozom\u00e1ln\u011b recesivn\u00ed<\/strong>.<\/p>\n\n\n\n<p><strong>Fenotyp u rhod\u00e9sk\u00fdch ridgeback\u016f<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>b\/b (hn\u011bd\u00fd\/j\u00e1trov\u00fd):<\/strong> hn\u011bd\u00fd (\u201ej\u00e1trov\u00fd\u201c) nos, pysky, o\u010dn\u00ed okraje a dr\u00e1py; odst\u00edn srsti se posouv\u00e1 k hn\u011bd\u00fdm t\u00f3n\u016fm.<\/li>\n\n\n\n<li><strong>B\/B nebo B\/b:<\/strong> \u010dern\u00fd pigment na nose\/k\u016f\u017ei, p\u0159ena\u0161e\u010di (B\/b) vypadaj\u00ed norm\u00e1ln\u011b.<\/li>\n<\/ul>\n\n\n\n<p><strong>Na\u0161e kohorta (n = 400):<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>B\/B (\u010dern\u00ed): 71 % (284)<\/li>\n\n\n\n<li>B\/b (p\u0159ena\u0161e\u010di): 25 % (100)<\/li>\n\n\n\n<li>b\/b (hn\u011bd\u00ed): 4 % (16)<\/li>\n<\/ul>\n\n\n\n<p><strong>D\u011bdi\u010dnost:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>B\/b \u00d7 B\/b:<\/strong> 25 % b\/b (hn\u011bd\u00ed), 50 % p\u0159ena\u0161e\u010di, 25 % B\/B<\/li>\n\n\n\n<li><strong>B\/b \u00d7 B\/B:<\/strong> 0 % b\/b; 50 % p\u0159ena\u0161e\u010di, 50 % B\/B<\/li>\n\n\n\n<li><strong>B\/B \u00d7 B\/B:<\/strong> 100 % B\/B <\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Hemofilie B (HEMB)<\/h2>\n\n\n\n<p>Hemofilie B je <strong>X-v\u00e1zan\u00e1<\/strong> d\u011bdi\u010dn\u00e1 krv\u00e1civost zp\u016fsoben\u00e1 nedostatkem nebo dysfunkc\u00ed sr\u00e1\u017eliv\u00e9ho faktoru IX (F9). Posti\u017een\u00ed psi maj\u00ed poruchu sr\u00e1\u017een\u00ed krve, tak\u017ee i drobn\u00e1 poran\u011bn\u00ed, chirurgick\u00e9 z\u00e1kroky nebo spont\u00e1nn\u00ed vnit\u0159n\u00ed krv\u00e1cen\u00ed mohou b\u00fdt \u017eivot ohro\u017euj\u00edc\u00ed.<\/p>\n\n\n\n<p><strong>Kdo je ohro\u017een?<\/strong><br>Proto\u017ee je HEMB v\u00e1zan\u00e1 na chromozom X, <strong>samci (XY)<\/strong> s patogenn\u00ed variantou jsou posti\u017eeni, zat\u00edmco <strong>samice (XX)<\/strong> jsou v\u011bt\u0161inou p\u0159ena\u0161e\u010dky. <\/p>\n\n\n\n<p><strong>V na\u0161\u00ed kohort\u011b<\/strong> nebyli zji\u0161t\u011bni \u017e\u00e1dn\u00ed posti\u017een\u00ed ani p\u0159ena\u0161e\u010di hemofilie B (<strong>N\/N: 400; P\/N: 0; P\/P: 0<\/strong>). Podle \u00fadaj\u016f od chovatel\u016f se nevyskytuj\u00ed p\u0159ena\u0161e\u010di ani u hemofilie A. Tyto v\u00fdsledky nazna\u010duj\u00ed, \u017ee <strong>hemofilie B i A jsou v populaci RR velmi vz\u00e1cn\u00e9<\/strong> a pravd\u011bpodobn\u011b se ji\u017e testovan\u00e9 varianty ani nevyskytuj\u00ed.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">\u010casn\u00e1 ztr\u00e1ta sluchu  (EOAD)<\/h2>\n\n\n\n<p>EOAD je d\u011bdi\u010dn\u00e9 onemocn\u011bn\u00ed, p\u0159i n\u011bm\u017e <strong>posti\u017een\u00fd rhod\u00e9sk\u00fd ridgeback ztr\u00e1c\u00ed sluch zhruba do 1\u20132 let v\u011bku<\/strong>. \u0160t\u011b\u0148ata se obvykle rod\u00ed sly\u0161\u00edc\u00ed; ztr\u00e1ta se rozv\u00edj\u00ed \u010dasn\u011b v \u017eivot\u011b.<\/p>\n\n\n\n<p><strong>Genetika<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Autosomaln\u011b recesivn\u00ed<\/strong> d\u011bdi\u010dnost.<\/li>\n\n\n\n<li><strong>Posti\u017een\u00fd jedinec (P\/P)<\/strong> vznik\u00e1, pokud jsou <strong>oba rodi\u010de p\u0159ena\u0161e\u010di<\/strong> (P\/N \u00d7 P\/N).<\/li>\n\n\n\n<li><strong>P\u0159ena\u0161e\u010di (P\/N)<\/strong> maj\u00ed norm\u00e1ln\u00ed sluch a EOAD se u nich nerozvine.<\/li>\n<\/ul>\n\n\n\n<p><strong>Na\u0161e kohorta (n = 400)<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Norm\u00e1ln\u00ed: 96% (384\/400)<\/strong><\/li>\n\n\n\n<li><strong>P\u0159ena\u0161e\u010di:<\/strong> ~4 % (16\/400)<\/li>\n\n\n\n<li><strong>Posti\u017een\u00ed (P\/P):<\/strong> 0 % detekov\u00e1no<\/li>\n<\/ul>\n\n\n\n<p><strong>Tip:<\/strong> Pokud existuje podez\u0159en\u00ed na EOAD, prove\u010fte genetick\u00e9 testy spolu s vy\u0161et\u0159en\u00edm sluchu metodou BAER a zaznamenejte v\u00fdsledky do chovatelsk\u00fdch a veterin\u00e1rn\u00edch z\u00e1znam\u016f.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">D\u011bdi\u010dn\u00e1 komorov\u00e1 arytmie (RRIVA)<\/h2>\n\n\n\n<p>P\u016fvodn\u00ed v\u00fdzkumn\u00e1 zpr\u00e1va t\u00fdmu veden\u00e9ho <strong>Dr. Kathryn Meurs<\/strong> popsala genetickou variantu spojovanou s d\u011bdi\u010dnou komorovou arytmi\u00ed u RR. <strong>N\u00e1sledn\u00e9 testov\u00e1n\u00ed u 400 RR<\/strong> v\u0161ak ukazuje, \u017ee varianta je v plemeni <strong>p\u0159\u00edli\u0161 \u010dast\u00e1<\/strong> a <strong>spolehliv\u011b nekoreluje<\/strong> s p\u0159\u00edtomnost\u00ed\/absenc\u00ed komorov\u00fdch arytmi\u00ed vedouc\u00edch k n\u00e1hl\u00e9mu \u00famrt\u00ed. Jin\u00fdmi slovy, <strong>prediktivn\u00ed hodnota testu je v t\u00e9to populaci n\u00edzk\u00e1<\/strong>. A\u010dkoliv byla p\u016fvodn\u011b identifikov\u00e1na kandid\u00e1tn\u00ed varianta, sou\u010dasn\u00e9 poznatky nazna\u010duj\u00ed, \u017ee <strong>nevysv\u011btluje riziko komorov\u00fdch arytmi\u00ed<\/strong> vedouc\u00edch k n\u00e1hl\u00e9mu \u00famrt\u00ed v \u0161ir\u0161\u00ed populaci RR; <strong>rutinn\u00ed genetick\u00e9 testov\u00e1n\u00ed t\u00e9to varianty proto pravd\u011bpodobn\u011b nen\u00ed p\u0159\u00ednosn\u00e9<\/strong>. V\u00edce informaco o RRIVA lze naj\u00edt v tomto \u010dl\u00e1nku: <a href=\"https:\/\/genocan.eu\/cs\/news\/cestina-ma-smysl-u-ridgebacku-testovat-dedicnou-arytmii-rr-iva\/\">M\u00e1 smysl testovat d\u011bdi\u010dnou komorovou arytmii (RR IVA) u Rhod\u00e9sk\u00fdch ridgeback\u016f? &#8211; GenoCan.eu<\/a><\/p>\n\n\n\n<p><strong>Frekvence varianty v na\u0161em souboru<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>N\/N \u2013 (standardn\u00ed varianta):<\/strong> n = 239 (60 %)<\/li>\n\n\n\n<li><strong>P\/N \u2013 (nosi\u010d alternativn\u00ed varianty):<\/strong> n = 151 (38 %)<\/li>\n\n\n\n<li><strong>P\/P \u2013 (homozygot alternativn\u00ed varianty):<\/strong> n = 10 (2,5 %)<\/li>\n<\/ul>\n\n\n\n<p><strong>Co to znamen\u00e1 v praxi<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Aktu\u00e1ln\u011b dostupn\u00fd genetick\u00fd test RRIVA m\u00e1 u RR velmi n\u00edzkou klinickou u\u017eitnou hodnotu.<\/strong><\/li>\n\n\n\n<li><strong>Negativn\u00ed v\u00fdsledek<\/strong> nevylu\u010duje arytmie a <strong>pozitivn\u00ed v\u00fdsledek<\/strong> diagn\u00f3zu nepotvrzuje.<\/li>\n\n\n\n<li>Rozhodov\u00e1n\u00ed o chovu \u010di klinick\u00e9m postupu <strong>nelze op\u00edrat pouze<\/strong> o tuto variantu.<\/li>\n<\/ul>\n\n\n\n<p><\/p>","protected":false},"excerpt":{"rendered":"<p>V\u00e1\u017een\u00ed chovatel\u00e9, r\u00e1di bychom se s v\u00e1mi pod\u011blili o data z genetick\u00e9ho testov\u00e1n\u00ed. V\u011b\u0159\u00edme, \u017ee v\u00e1m pomohou se l\u00e9pe zorientovat v genetice rhod\u00e9sk\u00fdch ridgeback\u016f. N\u00ed\u017ee je uvedena souhrnn\u00e1 tabulka zahrnuj\u00edc\u00ed v\u0161echny genetick\u00e9 choroby a znaky hodnocen\u00e9 v testov\u00e1n\u00ed bal\u00ed\u010dku RR PANEL + RRIVA (Rhod\u00e9sk\u00fd ridgeback &#8211; GenoCan.eu). \u00dadaje odr\u00e1\u017eej\u00ed v\u00fdsledky od 400 ps\u016f plemene rhod\u00e9sk\u00fd [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":3134,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[1,17],"tags":[],"class_list":["post-3132","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-nezarazene","category-news"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/genocan.eu\/cs\/wp-json\/wp\/v2\/posts\/3132","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/genocan.eu\/cs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/genocan.eu\/cs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/genocan.eu\/cs\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/genocan.eu\/cs\/wp-json\/wp\/v2\/comments?post=3132"}],"version-history":[{"count":0,"href":"https:\/\/genocan.eu\/cs\/wp-json\/wp\/v2\/posts\/3132\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/genocan.eu\/cs\/wp-json\/wp\/v2\/media\/3134"}],"wp:attachment":[{"href":"https:\/\/genocan.eu\/cs\/wp-json\/wp\/v2\/media?parent=3132"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/genocan.eu\/cs\/wp-json\/wp\/v2\/categories?post=3132"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/genocan.eu\/cs\/wp-json\/wp\/v2\/tags?post=3132"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}